Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer Schumi

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Statistics in Medicine|January 12, 2008
Resampling-based analyses of the effects of combinations of HIV genetic mutations on drug susceptibilityJennifer Schumi, Victor Degruttola
Trials|May 5, 2011
Through the looking glass: understanding non-inferiorityJennifer Schumi, Janet T Wittes
The International Journal of Biostatistics|March 17, 2010
Testing for associations with missing high-dimensional categorical covariatesJennifer Schumi, A Gregory DiRienzo, Victor DeGruttola
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|August 28, 2016
Assessment of the Cardiovascular Risk of Olmesartan Medoxomil-Based Treatment: Meta-Analysis of Individual Patient DataAntonia C Wang, Ulf Stellmacher, Jennifer Schumi, et al.
Health Affairs (Project Hope)|April 26, 2007
Changes in physician supply and scope of practice during a malpractice crisis: evidence from PennsylvaniaMichelle M Mello, David M Studdert, Jennifer Schumi, et al.
Therapeutic Innovation & Regulatory Science|February 20, 2020
Disease Modification in Alzheimer's Disease: Current ThinkingHong Liu-Seifert, Jennifer Schumi, Xiaopeng Miao, et al.
Lancet (London, England)|May 27, 2008
Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trialJean-Claude Tardif, John J V McMurray, Eric Klug, et al.
Hepatology Communications|July 14, 2022
Hepatic patatin-like phospholipase domain-containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humansElke Ericson, Linnéa Bergenholm, Anne-Christine Andréasson, et al.
JAMA Neurology|November 26, 2019
Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical TrialsAlette M Wessels, Pierre N Tariot, Jennifer A Zimmer, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Statistics in Medicine|January 12, 2008
Resampling-based analyses of the effects of combinations of HIV genetic mutations on drug susceptibilityJennifer Schumi, Victor Degruttola
Trials|May 5, 2011
Through the looking glass: understanding non-inferiorityJennifer Schumi, Janet T Wittes
The International Journal of Biostatistics|March 17, 2010
Testing for associations with missing high-dimensional categorical covariatesJennifer Schumi, A Gregory DiRienzo, Victor DeGruttola
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|August 28, 2016
Assessment of the Cardiovascular Risk of Olmesartan Medoxomil-Based Treatment: Meta-Analysis of Individual Patient DataAntonia C Wang, Ulf Stellmacher, Jennifer Schumi, et al.
Health Affairs (Project Hope)|April 26, 2007
Changes in physician supply and scope of practice during a malpractice crisis: evidence from PennsylvaniaMichelle M Mello, David M Studdert, Jennifer Schumi, et al.
Therapeutic Innovation & Regulatory Science|February 20, 2020
Disease Modification in Alzheimer's Disease: Current ThinkingHong Liu-Seifert, Jennifer Schumi, Xiaopeng Miao, et al.
Lancet (London, England)|May 27, 2008
Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trialJean-Claude Tardif, John J V McMurray, Eric Klug, et al.
Hepatology Communications|July 14, 2022
Hepatic patatin-like phospholipase domain-containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humansElke Ericson, Linnéa Bergenholm, Anne-Christine Andréasson, et al.
JAMA Neurology|November 26, 2019
Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical TrialsAlette M Wessels, Pierre N Tariot, Jennifer A Zimmer, et al.
Pageof 1